Tarsus Pharmaceuticals announced the commencement of an underwritten public offering of $100M of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All securities in the proposed offering are to be sold by Tarsus. Goldman Sachs & Co., BofA Securities, Guggenheim Securities, and Oppenheimer & Co. are acting as joint book-running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $60 from $55 at BofA
- Tarsus Pharmaceuticals price target raised to $59 from $55 at Oppenheimer
- Tarsus Pharmaceuticals price target raised to $57 from $50 at H.C. Wainwright
- Tarsus Pharmaceuticals price target raised to $50 from $40 at Barclays
- Tarsus Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.36)
